These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17985405)

  • 1. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis.
    Suarez-Almazor ME; Berrios-Rivera JP; Cox V; Janssen NM; Marcus DM; Sessoms S
    J Rheumatol; 2007 Dec; 34(12):2400-7. PubMed ID: 17985405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis.
    Hernández-García C; Vargas E; Abásolo L; Lajas C; Bellajdell B; Morado IC; Macarrón P; Pato E; Fernández-Gutiérrez B; Bañares A; Jover JA
    J Rheumatol; 2000 Oct; 27(10):2323-8. PubMed ID: 11036824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of psychological well being and disease activity in termination of an initial DMARD therapy.
    Listing J; Alten R; Brauer D; Eggens U; Gromnica-Ihle E; Hagemann D; Hauer R; Milleck D; Reuter U; Schlittgen R; Sörensen H; Zink A
    J Rheumatol; 1997 Nov; 24(11):2097-105. PubMed ID: 9375866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
    Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
    Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.
    Ward MM; Fries JF
    J Rheumatol; 1998 Mar; 25(3):408-16. PubMed ID: 9517756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician.
    Martin RW; Head AJ; René J; Swartz TJ; Fiechtner JJ; McIntosh BA; Holmes-Rovner M
    J Rheumatol; 2008 Apr; 35(4):618-24. PubMed ID: 18278840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice.
    Kahn KL; MacLean CH; Liu H; Rubenstein LZ; Wong AL; Harker JO; Chen WP; Fitzpatrick DM; Bulpitt KJ; Traina SB; Mittman BS; Hahn BH; Paulus HE
    Arthritis Rheum; 2006 Dec; 55(6):884-91. PubMed ID: 17139665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.
    Sihvonen S; Korpela M; Mustonen J; Huhtala H; Karstila K; Pasternack A
    J Rheumatol; 2006 Sep; 33(9):1740-6. PubMed ID: 16881099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort.
    Tavares R; Pope JE; Tremblay JL; Thorne C; Bykerk VP; Lazovskis J; Blocka KL; Bell MJ; Lacaille D; Hitchon CA; Fitzgerald AA; Fidler WK; Bookman AA; Henderson JM; Mosher DP; Sholter DE; Khraishi M; Haraoui B; Chen H; Li X; Laupacis A; Boire G; Tomlinson G; Bombardier C
    J Rheumatol; 2012 Nov; 39(11):2088-97. PubMed ID: 22896027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.